Objective. Osteoporosis has previously been reported to be twice as common in patients with RA as in controls, but these studies predate the introduction of aggressive management of RA. The aim of this study was to evaluate the prevalence and clinical predictors of osteoporosis in RA in a contemporary cohort and to develop a clinical tool for the identification of patients at risk.
Introduction
RA is associated with reduced bone density [13] and an increased risk of fragility fractures [4] . The pathophysiology of osteoporosis is complex, with contributions from general risk factors such as age, low body weight and postmenopausal status, along with disease-specific risk factors such as decreased mobility, corticosteroid use and production of proinflammatory cytokines [1, 2, 5, 6 ]. The importance of inflammatory disease as a pathogenic factor is emphasized by the fact that there is a positive correlation between disease activity and biochemical markers of bone resorption in RA [5] . Analysis of data from the Oslo registrar more than a decade ago indicated that $15% of RA patients had osteoporosis at the femoral neck as defined by DXA [1] . By comparing BMD values in the RA population with those from the manufacturer's reference range it was estimated that the risk of osteoporosis was increased 2-fold compared with the general population [1] . Since this time there have been major changes in the management of RA, with earlier and more aggressive use of synthetic DMARDs and deployment of biologic agents for patients who do not respond adequately [7] . Since there is evidence that control of inflammation with TNF-a inhibitors in RA may protect against systemic osteoporosis as well as preventing local bone erosions [8], we evaluated the prevalence and risk factors for the development of osteoporosis in a contemporary population of patients with RA presenting to a UK referral centre. We also developed an algorithm for the investigation of osteoporosis based on demographic and clinical risk factors for the disease within this population with the aim of better targeting DXA to patients at highest risk of having osteoporosis.
Patients and methods

Patients
The study cohort comprised all patients with RA who had been consecutively referred for DXA examination over a 24-month period between January 2009 and December 2010. In the resulting group of 304 patients, information was collected on gender, age, weight, height, alcohol intake, smoking, age at menopause, self-reported nonvertebral fractures and dietary calcium intake (assessed by food frequency questionnaire) at the time of the DXA scan according to routine practice. Details of disease duration, presence of RF and anti-CCP antibodies, erosions, inflammatory markers and anti-rheumatic and antiosteoporosis drug treatment were obtained through case note review. Inflammatory activity around the time of DXA examination was assessed by taking the average of three measurements of ESR and/or CRP performed within a 1-year window before the time of DXA. For statistical analysis we classified anti-rheumatic and anti-osteoporosis treatments into categories of current use, past use (>6 months before the DXA assessment) and ever use. We also collected information on the following comorbidities: cardiovascular disease, respiratory disease, cerebrovascular diseases, neurological disease, chronic renal and liver impairment, gastrointestinal disease, diabetes, thyroid disease and cancer. The frequency of osteoporosis in the RA population was compared with that in a population-based cohort of 903 subjects (709 women and 194 men) with an average age of 62.7 years (S.D. 10.3) who underwent DXA scanning as part of the Orkney Complex Disease Study (ORCADES). Details of this study have previously been described [9] . Relevant clinical and demographic information was collected for the controls as described for the cases and patients with RA were excluded. The prediction tool for osteoporosis described in this article was evaluated in an independent cohort of 171 RA patients (130 women and 41 men), average age 60. Information about the RA population was obtained through an audit of data that had been collected during routine clinical practice, hence ethical approval was not required.
Joint erosions
Hand radiographs were reviewed and scored for the presence of erosions and joint damage using the modified Larsen score as previously described [10] . In total, 140 sets of radiographs were available for analysis in the study cohort.
Measurements of BMD and fracture risk assessment
Measurements of BMD in all study populations were made by DXA at the lumbar spine (L1L4) and femoral neck using a QDR 4500 osteodensitometer (Hologic, Bedford, MA, USA). Vertebral fractures were initially ascertained on lateral spine images from T4 to L4 using the vertebral fracture assessment software of the DXA device. All vertebral fractures were subsequently confirmed on review of lateral X-rays of the thoracolumbar spine by radiologists according to normal clinical practice. Vertebral morphometry was not performed. Data on non-vertebral fractures was obtained by questionnaire and validated by analysis of case records and/or radiology reports.
Statistical analysis
Statistical analyses were performed using SPSS version 16.0 (SPSS, Chicago, IL, USA). A two-tailed independent Student's t-test was used for between-group comparisons of continuous data. If the variables were not normally distributed, a MannWhitney U test was applied. The chisquare test was used to evaluate for differences between categorical variables. Binary stepwise logistic regression was used to identify independent predictors of osteoporosis and fractures with inclusion of variables that were significantly (P < 0.05) associated with osteoporosis or fractures within the casecontrol analysis. The 95% CIs were calculated for differences between means and odds ratios (ORs) for paired data. Sensitivity and specificity were calculated according to standard methods and receiver operating characteristic (ROC) curves were constructed to identify models with the greatest area under the curve (AUC) and the simplest algorithm.
Results
Patient characteristics
Relevant clinical and demographic characteristics of the RA cohort are shown in Table 1 , broken down by gender. The mean age of the study population was 64 years and 81.9% were female. There was no significant difference between genders for age, BMI, current smoking status, seropositivity, disease duration, Larsen scores or fractures. As expected, men were taller and heavier than women, had significantly higher BMD values (P < 0.001), greater alcohol consumption (P = 0.016), had previously smoked more often (P = 0.034) and had higher CRP levels (P = 0.005). Nearly all of the patients (96.8%) had been treated with a DMARD, 53.6% had received glucocorticoids in the past and 33% were on either oral glucocorticoids or received regular intramuscular glucocorticoid injections at the time of the DXA scan. For patients on glucocorticoids, the average dose was 7.4 mg (S.D. 10) of prednisolone daily, with men receiving a significantly higher dose than women (P = 0.009) ( Table 1) . About one-quarter of patients (22.7%) had previously received anti-TNF treatment and 17.1% were receiving anti-TNF treatment at the time of the DXA scan. About one-fifth of patients (20.7%) were receiving a bisphosphonate and 26.6% were receiving calcium and vitamin D supplements.
Risk factors for osteoporosis
Relevant clinical and demographic variables in patients with and without osteoporosis as defined by a BMD T-score 4À2.5 on DXA at the spine or femoral neck are summarized in Table 2 . Osteoporosis was associated with female gender, age, BMI, years since menopause, number of co-morbidities, Larsen score, CRP and ESR.
There was no association between seropositivity for RF or CCP, previous or current glucocorticoid intake, anti-TNF treatment or DMARD therapy. As expected, vertebral and non-vertebral fractures were more common in patients with osteoporosis (P = 0.002 and P < 0.001, respectively).
Multivariable logistic regression was used to identify the independent predictors of osteoporosis. For this analysis, factors that were associated with osteoporosis in the casecontrol study at a P-value 40.05 were entered into the model, except CRP, which was excluded due to a large number of missing values. This revealed that the only independent predictors of osteoporosis were age (OR 1.08, 95% CI 1.03, 1.14) and BMI (OR 0.82, 95% CI 0.74, 0.91). The variables ESR (OR 1.01, 95% CI 0.99, 1.03), number of co-morbidities (OR 1.05, 95% CI 0.57, 1.96), gender (OR 0.44, 95% CI 0.14, 1.42), Larsen score (OR 1.01, 95% CI 0.99, 1.03) and years since menopause (OR 1.00, 95% CI 0.91, 1.10) failed to reach statistical significance. Overall the regression model explained 44% of the variance (Nagelkerke R 2 = 0.44). Further logistic regression analysis of the RA study group in which patients receiving bisphosphonates were excluded revealed very similar results to those mentioned above (data not shown).
Prevalence of osteoporosis in RA population vs controls
The levels of BMD at the lumbar spine and total hip in RA cases and controls are illustrated in Fig. 1 , broken down by gender. The levels of BMD were significantly lower in The number of observations available is shown in parentheses for variables with >1% of missing data.
www.rheumatology.oxfordjournals.org female RA cases as compared with female controls from the age of 45 years onwards (panels A and B). In males, total hip BMD was also significantly lower from the age of 45 years onwards. There was also a trend for lower spine BMD in men, but this was not significant at any individual time point (panels C and D). However, overall spine BMD in men was significantly lower in the RA population than in healthy controls [À0.7 (S.D. 1.6) vs À1.3 (S.D. 1.3), P < 0.001]. The overall prevalence of osteoporosis at the spine and total hip (as defined by a T-score <À2.5) in the cases and controls is summarized in Table 3 .
Development of a diagnostic algorithm
Based on the logistic regression analysis we developed an algorithm with which to predict the presence of osteoporosis in RA considering men and women separately. A ROC analyses showed that age and BMI alone were significant predictors of osteoporosis, with an AUC of 0.848 (95% CI 0.798, 0.891). Addition of other variables such as ESR, sex and number of co-morbidities into the model did not improve the ROC (AUC = 0.861, 95% CI 0.812, 0.910) curve significantly (P = 0.74) . Based upon this, we divided subjects into four BMI categories (<20, 2024.9, 2529.9 and >30) and four gender-specific age categories (<44.9, 4554.9, 5559.9 and >60 years for women and <49.9, 5059.9, 6069.9, >70 years for men). By allocating one point for each stratum we developed a risk stratification score based on age and BMI alone with which to identify patients at low, medium or high risk of having osteoporosis. The prevalence of osteoporosis (at either the spine or femoral neck) in RA patients according to these age and BMI strata is shown in Fig. 2 . Using these stratification variables we developed an algorithm, the osteoporosis prediction in RA (OPRA) tool. The OPRA risk assessment tool is freely accessible at http://www.opradxa.org.uk/opratool.htm. The performance of OPRA tool was evaluated in an independent cohort of 171 RA patients (41 men and 130 women) who underwent DXA scanning at our unit between 2010 and 2013. The tool had a sensitivity of 93.5% in women and 75% in men for the prediction of osteoporosis, with a specificity of 34.3% and 48.6%, respectively. The positive predictive value was 30.9% in women and 13.6% in men and the negative predictive value was 94.4% and 94.7%, respectively. We compared the performance of the OPRA tool with other tools that have been used for the prediction of osteoporosis, including the osteoporosis self-assessment tool (OST) [11], osteoporosis risk assessment instrument (ORAI) [12] and osteoporosis index of risk (OSIRIS) [13] . The results are shown in Table 4 . The OPRA tool was more sensitive than the other tools in predicting osteoporosis in both men and women but had lower specificity when compared with the other risk assessment tools. The only other prediction tool that has been tested in men (OST) was a poor predictor of osteoporosis in males (25% sensitivity). FIG. 1 BMD T-scores of the spine and total hip in healthy controls and RA patients HC: healthy controls; RA: patients with rheumatoid arthitis. *P < 0.05, **P < 0.01, ***P < 0.001 between RA patients and controls. Values are numbers (%) of individuals with osteoporosis in each age group. P-values refer to differences between cases and controls for each age group.
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Fracture prediction with the OPRA tool
We evaluated the ability of the OPRA tool to predict fractures in the study cohort. This showed that 97% of patients with vertebral fractures and 85% of patients with non-vertebral fractures would have been correctly identified by the OPRA tool. The specificity when using our model for fracture prediction was 27.4% and 26.1%, respectively. Further details are listed in supplementary  Table S2 , available at Rheumatology Online.
Discussion
This study of patients with RA has shown that the overall prevalence of osteoporosis was 26.5%, which is significantly higher than the prevalence of osteoporosis in a gender-and age-matched control cohort. These observations are in keeping with previous reports that recorded a prevalence of osteoporosis ranging between 17% and 32% in the spine and 15% and 36% in the hip [1, 2] . As in previous studies [1417] , the presence of osteoporosis in our cohort was associated with female gender, increasing age, years since menopause and low BMI. Disease activity has been identified previously as a risk factor for bone loss in RA [14, 1719] , and in keeping with this we observed a significant association between the levels of inflammatory markers and osteoporosis. However, neither of these variables emerged as independent predictors of bone density in the logistic regression analysis. Unfortunately, 28-joint DAS (DAS28) measurements were not recorded systematically in the study cohort, thus we were unable to evaluate possible associations between this measure of disease activity and osteoporosis. Although Larsen scores were associated with osteoporosis in the casecontrol study, they did not emerge as an independent predictor of osteoporosis in the logistic regression analysis. The relatively high prevalence of osteoporosis observed in this study, which is comparable to that observed in studies performed almost 15 years ago [1, 2] , indicates that the more aggressive approach to management of RA that has been widely adopted over recent years has not been accompanied by a major reduction in the proportion of RA patients who develop osteoporosis. This is in keeping with the fact that Haugeberg did not identify DMARD use as a determinant of systemic bone loss in RA patients followed over a 2-year period [20] .
Although there is evidence that anti-TNF therapy can arrest systemic bone loss in RA over a 12-month treatment period [8] , only one-quarter of our patients had received anti-TNF therapy. Thus the observations here suggest that in routine clinical practice, classical risk factors such as age, low BMI and gender play a predominant role in the pathogenesis of systemic osteoporosis in patients with RA [1, 21] . Although we did not observe an association between corticosteroid use and osteoporosis, this may be explained by the fact that the average dose of prednisolone was <10 mg/day and that about half (48.4%) of the patients on steroid therapy were also on boneprotective treatments (data not shown).
We found a positive association between the number of other co-morbidities and osteoporosis in the RA cohort. The likely explanation for this is that these co-morbidities are strongly related to age [22] , which could account for the fact that co-morbidity did not emerge as an independent predictor of osteoporosis in the logistic regression.
An interesting finding to emerge from this study was that there was a 10-year delay between the diagnosis of RA being made and the first request for DXA scanning. This indicates that DXA is not a priority investigation in routine clinical practice in patients with RA, especially in the first few years after diagnosis.
In an attempt to better target DXA screening of patients with RA, efforts have been made to develop prediction tools based on clinical risk factor analysis [23, 24] . In previous studies the risk criteria and cut-off values were chosen arbitrarily, which differs from the approach used here, where the OPRA tool was based on the outcome of logistic regression analysis. The negative predictive value and positive predictive value of the OPRA tool in our population (94.4% and 30.4%, respectively) did not differ significantly from existing tools that have been used for the prediction of osteoporosis in women, including the OST [11], the ORAI [12] and the OSIRIS [13] . However, the OPRA tool was clearly superior to the only other available tool (OST) in the prediction of osteoporosis ). The age categories were 0 (<44.9 women, <49.9 men), 1 (4554.9 women, 5059.9 men), 2 (5559.9 women, 6069.9 men) and 3 (>60 women and >70 men). The Osteoporosis Prediction in RA (OPRA) tool is based on a point allocation according to age and BMI.
in men (Table 4) . Further studies would be of interest to establish the performance of the OPRA tool compared with existing tools in other cohorts. We were unable to evaluate the Lems and Dijkman [23] and Haugeberg et al. models [24] in our population since HAQ data were not collected in our study, but a previous analysis by Nolla et al. [25] reported a sensitivity of 86% for the LemsDijkman tool and 82% for the Haugeberg tool in predicting osteoporosis in RA.
Rheumatology key messages
. Osteoporosis is a common problem in RA despite aggressive management with DMARDs and the use of biologic therapy. . Most RA patients with osteoporosis can be identified by a simple algorithm including age and BMI. 
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Supplementary data are available at Rheumatology Online. 
